Close Menu

A Myth

PureTech Ventures' John LaMattina this week says "there has never really been 'low-hanging fruit' in pharma R&D." Writing in Forbes, the former president of R&D at Pfizer says "the fact of the matter is that drug discovery has always been hard and that there have been spectacular failures over the years in pursuit of what its retrospectively viewed as 'low-hanging fruit,'" or easily attainable targets. "For decades, the fruit has always been hard to reach.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.